Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04-15

AUTHORS

Hiromi Tanii, Yoshihisa Shitara, Toshiharu Horie

ABSTRACT

PurposeLetrozole is an orally active aromatase inhibitor for the treatment of breast cancer. The objectives of this study were to examine the pharmacokinetic profile of letrozole in Japanese subjects and to identify factors that influence variability in the pharmacokinetics of letrozole using population pharmacokinetic (PPK) analysis.MethodsTwenty-five healthy postmenopausal Japanese women were enrolled in the study and received 2.5 mg letrozole once daily for 14 or 28 days. A PPK model was developed using NONMEM software. Age, body weight (WT), AST, ALT, total bilirubin, serum creatinine (CRE), and genotype of CYP2A6 were studied as covariates. Estrone, estrone sulfate, and estradiol in plasma were measured as pharmacodynamic markers.ResultsCYP2A6 genotype, CRE, and AST were significant covariates for apparent systemic clearance (CL/F), and WT was a significant covariate for apparent distribution volume (Vd/F). Population mean estimates of CL/F and Vd/F in subjects without CYP2A6 mutation were 1.03 × (CRE/0.70)−1.27 × (AST/17.5)−0.793 L/h and 94.2 × (WT/51.1)1.12 L respectively. CL/F in subjects possessing 1 and 2 CYP2A6 mutation alleles were 84.3% and 44.8% of the value in the subjects without mutation respectively. Estrogen levels fell to below detection limits in most subjects after letrozole administration. Three mild and transient adverse events (upper respiratory tract inflammation, arthralgia, and vomiting) were reported in the study.ConclusionsCYP2A6 genotype largely influences CL/F of letrozole. Genetic polymorphism of CYP2A6 and body weight will be causes of ethnic difference in PK. However, dose adjustment is not necessary, because of the wide therapeutic range. More... »

PAGES

1017

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-011-1042-3

DOI

http://dx.doi.org/10.1007/s00228-011-1042-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013431492

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21494765


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aromatase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aryl Hydrocarbon Hydroxylases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asian Continental Ancestry Group", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bilirubin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Weight", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Creatinine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 CYP2A6", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estradiol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Letrozole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polymorphism, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260\u20136875, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Translational Science Department, Novartis Pharma K.K., 4-17-30, Nishiazabu, Minato-ku, 106\u20138616, Tokyo, Japan", 
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260\u20136875, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanii", 
        "givenName": "Hiromi", 
        "id": "sg:person.01034340601.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034340601.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260\u20136875, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260\u20136875, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shitara", 
        "givenName": "Yoshihisa", 
        "id": "sg:person.0607677165.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607677165.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260\u20136875, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260\u20136875, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horie", 
        "givenName": "Toshiharu", 
        "id": "sg:person.015025434461.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015025434461.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1010669403283", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038910336", 
          "https://doi.org/10.1023/a:1010669403283"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11864-003-0014-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014342240", 
          "https://doi.org/10.1007/s11864-003-0014-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001887379", 
          "https://doi.org/10.1038/nrc1211"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-04-15", 
    "datePublishedReg": "2011-04-15", 
    "description": "PurposeLetrozole is an orally active aromatase inhibitor for the treatment of breast cancer. The objectives of this study were to examine the pharmacokinetic profile of letrozole in Japanese subjects and to identify factors that influence variability in the pharmacokinetics of letrozole using population pharmacokinetic (PPK) analysis.MethodsTwenty-five healthy postmenopausal Japanese women were enrolled in the study and received 2.5\u00a0mg letrozole once daily for 14 or 28\u00a0days. A PPK model was developed using NONMEM software. Age, body weight (WT), AST, ALT, total bilirubin, serum creatinine (CRE), and genotype of CYP2A6 were studied as covariates. Estrone, estrone sulfate, and estradiol in plasma were measured as pharmacodynamic markers.ResultsCYP2A6 genotype, CRE, and AST were significant covariates for apparent systemic clearance (CL/F), and WT was a significant covariate for apparent distribution volume (Vd/F). Population mean estimates of CL/F and Vd/F in subjects without CYP2A6 mutation were 1.03\u2009\u00d7\u2009(CRE/0.70)\u22121.27\u2009\u00d7\u2009(AST/17.5)\u22120.793\u2009L/h and 94.2\u2009\u00d7\u2009(WT/51.1)1.12\u2009L respectively. CL/F in subjects possessing 1 and 2 CYP2A6 mutation alleles were 84.3% and 44.8% of the value in the subjects without mutation respectively. Estrogen levels fell to below detection limits in most subjects after letrozole administration. Three mild and transient adverse events (upper respiratory tract inflammation, arthralgia, and vomiting) were reported in the study.ConclusionsCYP2A6 genotype largely influences CL/F of letrozole. Genetic polymorphism of CYP2A6 and body weight will be causes of ethnic difference in PK. However, dose adjustment is not necessary, because of the wide therapeutic range.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00228-011-1042-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "67"
      }
    ], 
    "keywords": [
      "CL/F", 
      "population pharmacokinetic analysis", 
      "pharmacokinetic analysis", 
      "body weight", 
      "healthy postmenopausal Japanese women", 
      "significant covariates", 
      "active aromatase inhibitors", 
      "pharmacokinetics of letrozole", 
      "postmenopausal Japanese women", 
      "transient adverse events", 
      "Japanese postmenopausal women", 
      "apparent systemic clearance", 
      "Vd/F", 
      "apparent distribution volume", 
      "wide therapeutic range", 
      "genotype of CYP2A6", 
      "serum creatinine", 
      "postmenopausal women", 
      "letrozole administration", 
      "adverse events", 
      "PPK model", 
      "pharmacodynamic markers", 
      "estrogen levels", 
      "therapeutic range", 
      "aromatase inhibitors", 
      "total bilirubin", 
      "systemic clearance", 
      "NONMEM software", 
      "breast cancer", 
      "estrone sulfate", 
      "pharmacokinetic profile", 
      "letrozole", 
      "Japanese women", 
      "distribution volume", 
      "most subjects", 
      "Japanese subjects", 
      "genetic polymorphisms", 
      "ethnic differences", 
      "creatinine", 
      "AST", 
      "subjects", 
      "CYP2A6", 
      "women", 
      "covariates", 
      "PurposeLetrozole", 
      "genotypes", 
      "weight", 
      "pharmacokinetics", 
      "estradiol", 
      "cancer", 
      "bilirubin", 
      "ALT", 
      "mutations", 
      "administration", 
      "study", 
      "clearance", 
      "age", 
      "mutation alleles", 
      "treatment", 
      "estrone", 
      "inhibitors", 
      "cause", 
      "markers", 
      "days", 
      "polymorphism", 
      "population", 
      "alleles", 
      "adjustment", 
      "plasma", 
      "factors", 
      "levels", 
      "differences", 
      "PK", 
      "events", 
      "volume", 
      "analysis", 
      "profile", 
      "objective", 
      "sulfate", 
      "variability", 
      "values", 
      "estimates", 
      "model", 
      "range", 
      "software", 
      "detection limit", 
      "limit", 
      "MethodsTwenty-five healthy postmenopausal Japanese women", 
      "ResultsCYP2A6 genotype", 
      "CYP2A6 mutation", 
      "CYP2A6 mutation alleles", 
      "ConclusionsCYP2A6 genotype"
    ], 
    "name": "Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women", 
    "pagination": "1017", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013431492"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-011-1042-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21494765"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-011-1042-3", 
      "https://app.dimensions.ai/details/publication/pub.1013431492"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_536.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00228-011-1042-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-011-1042-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-011-1042-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-011-1042-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-011-1042-3'


 

This table displays all metadata directly associated to this object as RDF triples.

257 TRIPLES      22 PREDICATES      140 URIs      129 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-011-1042-3 schema:about N0d2a612abbdb4e44bceab3604fb8b98a
2 N11aa498c65d34ba28304d860049f73a0
3 N231202f3b0d94cd6a7ea0ff99cc46ca3
4 N2ed131b3a98941baad29b7d376d9130e
5 N4105f7b457444a128486b24ca0cf9ca9
6 N680f42ae5d744ebc8aacd671296a6222
7 N6884d1c618fa4d94875bdab295f46ea9
8 N6f098a60309a44cfaa5d209fcbbfa7d3
9 N82e44b12c2f349cf914fc95ea064c82f
10 N98230d9d4c6a4c2198e6f046a86d3f44
11 N9d746a617ac04150a01f71cbecfaf903
12 Na36c4cfc8f5141f6a254cdbff4e121ac
13 Nb439cf19917b4f5da9f185706f6ff7ea
14 Nbdb7bee514434c9b8c45fe59383d0647
15 Nc2b35fd598a14abfb4550ac5a9a0cab3
16 Nc724ca99f32d4b5d85d51304bd75eaf8
17 Ncd30a272b73e4d59a2d0912c0a741f9e
18 Ndb7136b32bf84b12b014ee5bf76e4e8a
19 Nfe8642e976f048c1a6cdc77e640d1c51
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N887f19ddf5bf4127923628c97acb909d
23 schema:citation sg:pub.10.1007/s11864-003-0014-y
24 sg:pub.10.1023/a:1010669403283
25 sg:pub.10.1038/nrc1211
26 schema:datePublished 2011-04-15
27 schema:datePublishedReg 2011-04-15
28 schema:description PurposeLetrozole is an orally active aromatase inhibitor for the treatment of breast cancer. The objectives of this study were to examine the pharmacokinetic profile of letrozole in Japanese subjects and to identify factors that influence variability in the pharmacokinetics of letrozole using population pharmacokinetic (PPK) analysis.MethodsTwenty-five healthy postmenopausal Japanese women were enrolled in the study and received 2.5 mg letrozole once daily for 14 or 28 days. A PPK model was developed using NONMEM software. Age, body weight (WT), AST, ALT, total bilirubin, serum creatinine (CRE), and genotype of CYP2A6 were studied as covariates. Estrone, estrone sulfate, and estradiol in plasma were measured as pharmacodynamic markers.ResultsCYP2A6 genotype, CRE, and AST were significant covariates for apparent systemic clearance (CL/F), and WT was a significant covariate for apparent distribution volume (Vd/F). Population mean estimates of CL/F and Vd/F in subjects without CYP2A6 mutation were 1.03 × (CRE/0.70)−1.27 × (AST/17.5)−0.793 L/h and 94.2 × (WT/51.1)1.12 L respectively. CL/F in subjects possessing 1 and 2 CYP2A6 mutation alleles were 84.3% and 44.8% of the value in the subjects without mutation respectively. Estrogen levels fell to below detection limits in most subjects after letrozole administration. Three mild and transient adverse events (upper respiratory tract inflammation, arthralgia, and vomiting) were reported in the study.ConclusionsCYP2A6 genotype largely influences CL/F of letrozole. Genetic polymorphism of CYP2A6 and body weight will be causes of ethnic difference in PK. However, dose adjustment is not necessary, because of the wide therapeutic range.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N12c6325f5f3143dc9f5afb100280acc8
33 N18d7d1ca1d3c4708a1170a32a28d6938
34 sg:journal.1054337
35 schema:keywords ALT
36 AST
37 CL/F
38 CYP2A6
39 CYP2A6 mutation
40 CYP2A6 mutation alleles
41 ConclusionsCYP2A6 genotype
42 Japanese postmenopausal women
43 Japanese subjects
44 Japanese women
45 MethodsTwenty-five healthy postmenopausal Japanese women
46 NONMEM software
47 PK
48 PPK model
49 PurposeLetrozole
50 ResultsCYP2A6 genotype
51 Vd/F
52 active aromatase inhibitors
53 adjustment
54 administration
55 adverse events
56 age
57 alleles
58 analysis
59 apparent distribution volume
60 apparent systemic clearance
61 aromatase inhibitors
62 bilirubin
63 body weight
64 breast cancer
65 cancer
66 cause
67 clearance
68 covariates
69 creatinine
70 days
71 detection limit
72 differences
73 distribution volume
74 estimates
75 estradiol
76 estrogen levels
77 estrone
78 estrone sulfate
79 ethnic differences
80 events
81 factors
82 genetic polymorphisms
83 genotype of CYP2A6
84 genotypes
85 healthy postmenopausal Japanese women
86 inhibitors
87 letrozole
88 letrozole administration
89 levels
90 limit
91 markers
92 model
93 most subjects
94 mutation alleles
95 mutations
96 objective
97 pharmacodynamic markers
98 pharmacokinetic analysis
99 pharmacokinetic profile
100 pharmacokinetics
101 pharmacokinetics of letrozole
102 plasma
103 polymorphism
104 population
105 population pharmacokinetic analysis
106 postmenopausal Japanese women
107 postmenopausal women
108 profile
109 range
110 serum creatinine
111 significant covariates
112 software
113 study
114 subjects
115 sulfate
116 systemic clearance
117 therapeutic range
118 total bilirubin
119 transient adverse events
120 treatment
121 values
122 variability
123 volume
124 weight
125 wide therapeutic range
126 women
127 schema:name Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women
128 schema:pagination 1017
129 schema:productId N3273b0471e3f4959977aaf392e5dd39e
130 Na700a9fb14e84c71b4dfcd0b3ce07c3c
131 Nda2b218d77ac479e96272491caa459be
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013431492
133 https://doi.org/10.1007/s00228-011-1042-3
134 schema:sdDatePublished 2022-01-01T18:24
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher N7d5c75b263e74d329d4464a0412f7513
137 schema:url https://doi.org/10.1007/s00228-011-1042-3
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N0d2a612abbdb4e44bceab3604fb8b98a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 N11aa498c65d34ba28304d860049f73a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Bilirubin
146 rdf:type schema:DefinedTerm
147 N12c6325f5f3143dc9f5afb100280acc8 schema:issueNumber 10
148 rdf:type schema:PublicationIssue
149 N18d7d1ca1d3c4708a1170a32a28d6938 schema:volumeNumber 67
150 rdf:type schema:PublicationVolume
151 N231202f3b0d94cd6a7ea0ff99cc46ca3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Postmenopause
153 rdf:type schema:DefinedTerm
154 N2ed131b3a98941baad29b7d376d9130e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Genotype
156 rdf:type schema:DefinedTerm
157 N3273b0471e3f4959977aaf392e5dd39e schema:name doi
158 schema:value 10.1007/s00228-011-1042-3
159 rdf:type schema:PropertyValue
160 N4105f7b457444a128486b24ca0cf9ca9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Estradiol
162 rdf:type schema:DefinedTerm
163 N680f42ae5d744ebc8aacd671296a6222 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Asian Continental Ancestry Group
165 rdf:type schema:DefinedTerm
166 N6884d1c618fa4d94875bdab295f46ea9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Triazoles
168 rdf:type schema:DefinedTerm
169 N6f098a60309a44cfaa5d209fcbbfa7d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 N7d5c75b263e74d329d4464a0412f7513 schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 N82e44b12c2f349cf914fc95ea064c82f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 N887f19ddf5bf4127923628c97acb909d rdf:first sg:person.01034340601.30
178 rdf:rest N97a7ed4bdb8b48e79d107af34e68ef8a
179 N97a7ed4bdb8b48e79d107af34e68ef8a rdf:first sg:person.0607677165.24
180 rdf:rest Nbbc1d32992264f90848f7b346624f59d
181 N98230d9d4c6a4c2198e6f046a86d3f44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Polymorphism, Genetic
183 rdf:type schema:DefinedTerm
184 N9d746a617ac04150a01f71cbecfaf903 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Aromatase Inhibitors
186 rdf:type schema:DefinedTerm
187 Na36c4cfc8f5141f6a254cdbff4e121ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Creatinine
189 rdf:type schema:DefinedTerm
190 Na700a9fb14e84c71b4dfcd0b3ce07c3c schema:name pubmed_id
191 schema:value 21494765
192 rdf:type schema:PropertyValue
193 Nb439cf19917b4f5da9f185706f6ff7ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Nitriles
195 rdf:type schema:DefinedTerm
196 Nbbc1d32992264f90848f7b346624f59d rdf:first sg:person.015025434461.42
197 rdf:rest rdf:nil
198 Nbdb7bee514434c9b8c45fe59383d0647 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Aryl Hydrocarbon Hydroxylases
200 rdf:type schema:DefinedTerm
201 Nc2b35fd598a14abfb4550ac5a9a0cab3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Estrone
203 rdf:type schema:DefinedTerm
204 Nc724ca99f32d4b5d85d51304bd75eaf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Antineoplastic Agents
206 rdf:type schema:DefinedTerm
207 Ncd30a272b73e4d59a2d0912c0a741f9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Body Weight
209 rdf:type schema:DefinedTerm
210 Nda2b218d77ac479e96272491caa459be schema:name dimensions_id
211 schema:value pub.1013431492
212 rdf:type schema:PropertyValue
213 Ndb7136b32bf84b12b014ee5bf76e4e8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Cytochrome P-450 CYP2A6
215 rdf:type schema:DefinedTerm
216 Nfe8642e976f048c1a6cdc77e640d1c51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Letrozole
218 rdf:type schema:DefinedTerm
219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
220 schema:name Medical and Health Sciences
221 rdf:type schema:DefinedTerm
222 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
223 schema:name Oncology and Carcinogenesis
224 rdf:type schema:DefinedTerm
225 sg:journal.1054337 schema:issn 0031-6970
226 1432-1041
227 schema:name European Journal of Clinical Pharmacology
228 schema:publisher Springer Nature
229 rdf:type schema:Periodical
230 sg:person.01034340601.30 schema:affiliation grid-institutes:grid.136304.3
231 schema:familyName Tanii
232 schema:givenName Hiromi
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034340601.30
234 rdf:type schema:Person
235 sg:person.015025434461.42 schema:affiliation grid-institutes:grid.136304.3
236 schema:familyName Horie
237 schema:givenName Toshiharu
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015025434461.42
239 rdf:type schema:Person
240 sg:person.0607677165.24 schema:affiliation grid-institutes:grid.136304.3
241 schema:familyName Shitara
242 schema:givenName Yoshihisa
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607677165.24
244 rdf:type schema:Person
245 sg:pub.10.1007/s11864-003-0014-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1014342240
246 https://doi.org/10.1007/s11864-003-0014-y
247 rdf:type schema:CreativeWork
248 sg:pub.10.1023/a:1010669403283 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038910336
249 https://doi.org/10.1023/a:1010669403283
250 rdf:type schema:CreativeWork
251 sg:pub.10.1038/nrc1211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001887379
252 https://doi.org/10.1038/nrc1211
253 rdf:type schema:CreativeWork
254 grid-institutes:grid.136304.3 schema:alternateName Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260–6875, Chiba, Japan
255 schema:name Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, 260–6875, Chiba, Japan
256 Translational Science Department, Novartis Pharma K.K., 4-17-30, Nishiazabu, Minato-ku, 106–8616, Tokyo, Japan
257 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...